December 2013

Pomalidomide (Pomalyst) rode impressive trial results to accelerated FDA approval this year, and Kenneth Anderson thinks it will prove a valuable new tool in the fight against multiple myeloma

New treatments for HER2-positive (HER2+) tumors have dominated media coverage of breast cancer breakthroughs over the past year, but William Gradishar sees promise on many fronts.

Harnessing multiple components of the immune system to fight cancer is the focus of NewLink Genetics' clinical pipeline.

The anti-PD-1 monoclonal antibody pidilizumab showed promising clinical activity and was safely administered to patients with diffuse large B-cell lymphoma after autologous hematopoietic stem-cell transplantation.

The renaissance in immunology is already affecting treatment paradigms for a variety of gynecologic cancers, and the impact is only likely to expand.

The FDA approval of two anti-CD20 antibodies-ofatumumab and, recently, obinotuzumab-has greatly advanced the outlook for managing chronic lymphocytic leukemia.

Mark G. Kris, MD, from the Memorial Sloan-Kettering Cancer Center, describes the new drugs and other emerging trends in lung cancer.

Brentuximab vedotin (Adcetris) should not be given with bleomycin as a first-line therapy for patients with advanced-stage Hodgkin lymphoma

Several new drugs have recently shown promise for the treatment of gastric cancer, including rilotumumab, ramucirumab, and anti-HER2 agents, according to a presentation at the 2013 Chemotherapy Foundation Symposium.

San Diego-based Ambit Biosciences is staking its success on the kinome, a set of protein kinases in the genome and an important source for targeted therapies in oncology.

Like you, I get up every day and look at the stack of journals I know I need to read but cannot imagine when I will find the time.

Researchers at the Seattle Cancer Care Alliance (SCCA) have optimized special methods for modifying T cells to target specific cancer cells in patients with blood cancers.

The genomic instability inherent in serous ovarian cancer poses treatment challenges, but it also represents a target which can be exploited through the use of PARP inhibitors

This year's approval of radium-223 chloride (Xofigo) continues the 4-year run of important new prostate cancer drugs, and Matthew Cooperberg thinks the run will continue over the next few years.